首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1643913

全球预防保健市场 - 2025-2032

Global Preventive Healthcare Market - 2025-2032

出版日期: 2025年01月27日 | 出版商:

DataM Intelligence | 英文 235 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球预防保健市场达到3,881.7亿美元，预计2032年将达到11,616.5亿美元，2024-2032年预测期间复合年增长率为14.1%。

预防保健是指定期进行健康检查，并采取必要措施预防任何疾病的发生。在成年人中，预防保健是指对糖尿病、心血管疾病、癌症等疾病进行早期筛检；在儿童中，疫苗接种、新生儿筛检、遗传性疾病基因检测等是主要的预防保健措施。

市场动态：

驱动程式和限制

政府在预防性医疗保健方面的措施和投资不断增加

全球各国政府不断采取的促进预防性医疗保健实践的措施预计将在未来显着提振市场。随着慢性病盛行率的上升，治疗医学的整体经济负担更高，因此各国政府正将重点转向预防医学。对疫苗接种、公共卫生监测、疾病筛检计划、早期诊断和宣传活动等各种预防性医疗保健领域的投资正在不断增长。

例如，2024年，法国AIS Agence de l'innovation en sante宣布投资170万欧元（约1.8亿美元），用于支持新型设备的开发以及与预防保健相关的其他研究活动。 AIS重点关注儿童健康、心理健康、不孕症、慢性病、传染病、罕见疾病、成瘾等八个领域，为大型项目、环境因素研究计划等三个发展领域分配了预算以及开发预防技术的工业项目。

此外，Gavi也表示，在2026年至2030年期间，Gavi和疫苗合作伙伴计划以巨额投资加强全球疫苗接种计画。在此期间，疫苗联盟计划透过国内共同融资和自筹资金的疫苗计画提供40亿美元的财政捐助，拯救8至900万人的生命，并为5亿儿童提供免疫。

这些投资可以显着改善公共卫生结果，减轻疾病负担，减少昂贵的治疗和住院的需要。

预防性医疗保健实践的高成本可能会限制市场成长。

个人可能会发现预防性医疗措施昂贵，特别是如果他们必须自掏腰包的话。这可能会阻碍人们积极参与预防计划或定期进行筛检和检查。实施全面的预防性医疗保健计划通常需要在基础设施、技术和人员培训方面进行大量财务投资。

Preventive healthcare refers to the routine practice of healthcare checkups, and taking necessary measures to prevent the occurrence of any kind of disease. Among the adult population, preventive healthcare refers to early screening for conditions such as diabetes, cardiovascular diseases, cancers, etc, and among children, vaccination, newborn screening, genetic testing for inherited diseases, etc are the major preventive healthcare steps.

Market Dynamics: Drivers & Restraints

Rising government initiatives and investments in preventive healthcare

The rising initiatives by governments across the globe to promote the practice of preventive healthcare are expected to significantly boost the market in the future. With the rising prevalence of chronic conditions, the overall economic burden is higher for curative medicine, hence the governments are shifting their focus to preventive medicine. The investments are growing in various preventive healthcare sectors such as vaccinations, public health monitoring, disease screening programs, early-stage diagnostics, and awareness campaigns.

For instance, in 2024, Agence de l'innovation en sante, AIS of France announced an investment of €170 (~ US$180) million to support the development of novel devices and other research activities related to preventive healthcare. With a focus on eight fields such as children's health, mental health, infertility, chronic diseases, infectious disease, rare diseases, and addiction, AIS has allocated the budget for three development areas such as large-scale projects, a research program on environmental factors and industrial projects that develop preventive technologies.

Moreover, Gavi has stated that between the period of 2026-2030, Gavi and the vaccine partners plan to strengthen the global vaccination programs with huge investments. During the period, the vaccine alliance plans to save 8 to 9 million lives and immunize 500 million children through a financial contribution of US$ 4 billion through domestic co-financing and self-funded vaccine programs.

These investments can significantly improve public health outcomes, reduce the disease burden, reducing the need for expensive treatments and hospitalizations.

The high cost of preventive healthcare practices may restrain the market growth.

Individuals may find preventive healthcare measures expensive, especially if they have to bear the costs out-of-pocket. This can discourage people from actively participating in preventive programs or getting regular screenings and check-ups. Implementation of comprehensive preventive healthcare programs often requires substantial financial investments in infrastructure, technology, and personnel training.

Segment Analysis

The global preventive healthcare market is segmented based on type, application, and region.

Early-stage diagnostics in the application segment is expected to grow with the highest CAGR in the forecast period.

Early-stage diagnostics play a crucial role in preventive healthcare as they aid in the early detection of preventable diseases. Early-stage diagnosis refers to the identification of the disease risk and burden before the incidence of symptoms or in the initial stages. This can significantly reduce the disease and economic burden on the patient. There are several tools available for early-stage detection of various chronic and life-threatening diseases such as diabetes, heart stroke & other cardiovascular diseases, cancer, infectious diseases, etc. This early-stage detection allows for timely intervention before the disease incidence, and improve the overall patient outcome. The market for early-stage diagnostics is expected to significantly grow in the forecast period due to rising investments, launch of novel diagnostic tools and the increasing adoption rate by the population.

For instance, in December 2024, Strand Life Sciences, a subsidiary of Reliance Industries of India launched a new early cancer detection tool called CancerSpot. The test can detect multiple cancers from blood samples using Strand Life Science's proprietary sequencing technology. Moreover, in February 2024, All India Institute of Medical Sciences (AIIMS) Delhi launched a new Artificial Intelligence (AI) platform that enables the early detection of gynecological cancers.

Geographical Analysis

Asia-Pacific is expected to grow with the highest CAGR in the preventive healthcare market.

Asia-Pacific region is not only well known for its higher population but also for the advancing healthcare landscape. The growing elderly population and increasing prevalence of chronic non-communicable diseases are making the population highly aware of the importance of preventive measures. As per the World Health Organization statements 62% of all deaths in South East Asia are due to non-communicable diseases which account for 9 million persons. All these deaths could be avoided by the practice of preventive healthcare through early disease diagnosis, risk assessments, regular disease screening, health monitoring, etc. However, the practices of healthcare are rapidly changing in the region. The population of Asia-Pacific is rapidly becoming aware of the importance of preventive medicine. To further propel the practice, governments across the region are actively alocating budgets, launching screening programs, awareness campaigns for preventive healthcare.

For instance, for the financial year 2024-25, India's Ministry of Health and Family Welfare (MoHFW) has allocated a budget of Rs. 87,657 crores (~US$10.2 billion) for the for the Department of Health & Family Welfare (DoHFW). Moreover, Rs. 70,051 crore (~US$8.1 billion) grants for health through the local Governments were provided by the 15th Finance Commission. The health budget has seen a rise of 85% from the fiscal year 2017-18. In addition, till 10th December 2024, 1,75,418 Ayushman Arogya Mandirs (AAMs) have been established and operationalized whose function is to perform primary healthcare services including preventive medicine.

This huge makeshift in the healthcare practices in one of the fastest growing economies i.e., India reflects the region's investment in preventive healthcare.

Competitive Landscape

The major global players in the preventive healthcare market are Pfizer Inc., AstraZeneca, GSK plc., Sanofi, Merck & Co., Inc., Meridian Bioscience, Exact Sciences Corporation., GRAIL, Inc., Myriad Genetics, Inc., Apple Inc., SAMSUNG, Fitbit, Bio-Rad Laboratories, Inc., Revvity and Trivitron Healthcare among others.

Emerging Players

The emerging players in the preventive healthcare market include Chronomics Limited., CEREBRA.AI LTD, Aidoc, and iSchemaView, Inc. and ataraxis.ai, among others.

Key Developments

In October 2024, ataraxis.ai launched a novel AI-powered diagnostic test called Ataraxis Breast for precise and early detection of breast cancer. This tool can help physicians to prescribe personalized treatment to the patient and significantly improve the overall clinical outcome.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing innovations, and novel platform developments and forecasts upcoming technological advancements.
Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates user feedback and data into product/technology development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global preventive healthcare market report would provide approximately 69 tables, 48 figures, and 235 pages.

Target Audience 2023

Manufacturers: Pharmaceutical, Biotech Companies, Tech Leaders.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: R&D Professionals, Tech Innovators, AI Professionals.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising government initiatives and investments in preventive healthcare
  - 4.1.1.2. Rising awareness and practices of preventive healthcare
  - 4.1.1.3. Technological innovations for early disease screening
- 4.1.2. Restraints
  - 4.1.2.1. High cost of preventive healthcare
- 4.1.3. Opportunities
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Epidemiology
5.3. Pricing Analysis
5.4. Pipeline Analysis
5.5. Patent Analysis
5.6. Regulatory Analysis

6. By Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 6.1.2. Market Attractiveness Index, By Type
6.2. Products*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Services

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Vaccination*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Early-Stage Diagnostics
  - 7.2.3.1. Cancer
  - 7.2.3.2. Diabetes
  - 7.2.3.3. Cardiovascular Diseases
  - 7.2.3.4. Hereditary Testing
  - 7.2.3.5. New Born Screening
  - 7.2.3.6. Others
7.3. Health Monitoring/Screening
7.4. Condition Management
7.5. Others

8. By Region

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.5.1. U.S.
  - 8.2.5.2. Canada
  - 8.2.5.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.5.1. Germany
  - 8.3.5.2. U.K.
  - 8.3.5.3. France
  - 8.3.5.4. Spain
  - 8.3.5.5. Italy
  - 8.3.5.6. Rest of Europe
8.4. South America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.5.1. Brazil
  - 8.4.5.2. Argentina
  - 8.4.5.3. Rest of South America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.5.1. China
  - 8.5.5.2. India
  - 8.5.5.3. Japan
  - 8.5.5.4. South Korea
  - 8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis

10. Company Profiles

Key Market Players

10.1. Pfizer Inc.*
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio
- 10.1.3. Financial Overview
- 10.1.4. Key Developments
- 10.1.5. SWOT Analysis
10.2. AstraZeneca
10.3. GSK plc.
10.4. Sanofi
10.5. Merck & Co., Inc.
10.6. Meridian Bioscience
10.7. Exact Sciences Corporation.
10.8. GRAIL, Inc.
10.9. Myriad Genetics, Inc.
10.10. Apple Inc.
10.11. SAMSUNG
10.12. Fitbit
10.13. Bio-Rad Laboratories, Inc.
10.14. Revvity
10.15. Trivitron Healthcare
Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

11. Appendix

11.1. About Us and Services
11.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球预防保健市场 - 2025-2032

Global Preventive Healthcare Market - 2025-2032

市场动态：

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

第 5 章：产业分析

第 6 章：按类型

第 7 章：按申请

第 8 章：按地区

第 9 章：竞争格局

第 10 章：公司简介

第 11 章：附录